Mediaboss Marketing

An Islamic State suicide bombing outside Kabul airport last week killed at least 92 people, including 13 US service members, as thousands of desperate Afghans were at the airport hoping to get on any evacuation flight out of the country in order to flee the Taliban.

The Islamic State in Khorasan Province issued a statement claiming responsibility for the suicide bombing attack, which reminded people of similar complex, vicious and cruel assaults during the reign of the original organization in Syria and Iraq.

Despite claims that the Islamic State, or ISIS, group was defeated in the area of the Levant, affiliated branches sprouted in Yemen, Sinai and North Africa, including the groups regional chapter in Afghanistan called Islamic State-Khorasan or ISIS-K.

Khorasan is a historical name for the region, taking in parts of what is today Pakistan, Iran, Afghanistan and Central Asia.

The Islamic State organization declared a caliphate in Iraq and Syria in 2014, when its fighters rolled over Iraqi army forces. ISIS took advantage of the chaos in neighboring Syria, controlling large swaths of land in the war-torn country.

That year, fighters from the Pakistani Taliban led by Pakistani national Hafiz Saeed Khan split and joined militants in Afghanistan to form an ISIS regional chapter, pledging allegiance to its leader Abu Bakr al-Baghdadi.

ISIS-K began operating in Afghanistan in 2015 when the top leadership of ISIS recognized the branch. It established roots in northeastern Afghanistan, particularly Kunar, Nangarhar and Nuristan provinces.

With the US-backed government out of power, the Taliban have now come face to face with ISIS-K.

According to a report by the Center for Strategic and International Studies (CSIS), ISIS-Ks founder died in a US airstrike in 2016.

The US has conducted several attacks against the group in the past, killing dozens of ISIS-K fighters in 2017, when US warplanes dropped the mother of all bombs the biggest one in the US arsenal on a cave the group was using as a hideout. That bombing killed 96 ISIS-K members.

Analysts estimate that the US military had killed 75% of ISIS-K fighters.

Despite the deadly attack, the United Nations estimates that ISIS-K still has between 500 and 2,000 fighters in Afghanistans Konar and Nangahar provinces. Smaller cells are scattered across the country.

But attacks like the ones last Thursday will be used to recruit new members for the group.

With the chaotic US withdrawal, and Taliban success in taking over control of most of Afghanistan, membership to Taliban and ISIS-K is likely to spike as the country becomes a fertile ground to attract new fighters for these groups.

Wake up to the Trusted Mideast News source Mideast Daily News Email

The UN Security Council estimates as many as 10,000 foreign fighters from Central Asia, southern Russia, Pakistan and western China have rushed into Afghanistan in recent months.

And while a majority have joined the Taliban or al-Qaida, others joined ISIS-K.

The Islamic States Afghanistan-Pakistan regional chapter has been responsible for some of the most lethal attacks in recent years, its fighters charged with the most gruesome assaults on civilians in both countries, at mosques, shrines, public squares and even hospitals.

The group has especially targeted Muslims from sects it considers heretical, including Shiites.

ISIS-K conducted at least 77 attacks in Afghanistan during the first four months of 2021, according to a UNSC report in June, a huge increase from the 21 attacks during the same period in 2020.

Talibans ideology centers around enforcing its version of sharia law in Afghanistan, while ISIS-K has its eyes on a bigger prize and that is to establish an Islamic caliphate across the Middle East and Asia.

Its no secret that the two groups are rivals, and last Thursdays deadly bombing with the many fatalities and chaos that ensued as a result, had another goal in ISIS-Ks mind, and that is to undermine the Taliban.

A new leader was appointed to head the group late last year, Shahab al-Muhajir, an Arab from the Middle East, believed to be Iraqi, who previously served with al-Qaida in the Afghanistan-Pakistan region.

A UN report in July described al-Muhajir as ambitious, and called operations under his leadership active and dangerous.

Following last Thursdays deadly suicide bombing at Kabul airport, the US military said Friday it had carried out a drone strike against a planner of the Islamic State-Khorasan.

The unmanned airstrike occurred in the Nangarhar Province of Afghanistan. Initial indications are that we killed the target, said Captain Bill Urban of the US Central Command.

A Sunday explosion in the Afghan capital, Kabul, reportedly was an American retaliatory drone strike on a vehicle carrying multiple Islamic State suicide bombers on the way to the Kabul airport.

Go here to see the original:
Chaotic US Withdrawal, Taliban Control of Afghanistan May Give Rise to ISIS Branch - The Media Line

FOR IMMEDIATE RELEASE:Aug. 30, 2021

COLUMBIA, S.C. Sickle cell disease is a serious genetic disorder that impacts many families around the country and around the world. The South Carolina Department of Health and Environmental Control (DHEC) supports the annual recognition of September as National Sickle Cell Awareness Month to help focus attention on the need for further research and treatment of sickle cell disease.

As the most common inherited blood disorder in the United States, sickle cell disease (SCD) currently affects approximately 100,000 Americans, including more than 4,000 South Carolinians who have the disease. Complications from SCD include pain attacks that can cause the individual to need hospitalization. Other potentially life-threatening complications include infections, stroke, and organ damage.

Because symptoms and complications of SCD can vary, treatment options are different for each person depending on their symptoms. The only known cure for SCD is bone marrow or stem cell transplant.

Sickle cell disease can be a debilitating and life-threatening disease for those who have it, and it can also affect the lives of their family and friends, said Dr. Brannon Traxler, DHEC Public Health Director. While September is National Sickle Cell Awareness Month, increasing public knowledge about sickle cell should be a year-long initiative.

The theme of this years monthly recognition is Sickle Cell Matters, which underscores the need to raise awareness about the daily struggles of those living with SCD as well as the need to address the stereotypes and stigmas associated with people who have the disorder.

Babies are born with SCD; it isnt a disease that someone can develop later in life. In people who are born with SCD, both copies of a hemoglobin gene are abnormal. A person born with one abnormal copy of the gene and one normal copy has "sickle cell trait." People with sickle cell trait usually don't have symptoms although in rare cases they can experience complications of SCD like pain crises. When two people with sickle cell trait have a child, there is a 25-percent chance the child will have SCD. Even if only one parent has a sickle cell trait, their child could still have an increased risk of inheriting a type of sickle cell disease.

Blood tests can confirm whether a person has sickle cell trait or SCD, and the disorders are commonly detected during newborn health screenings.

SCD disproportionally affects those with African ancestry or who identify as Black. The disease also can be found in anyone with genetic makeup from a part of the world where malaria is more widely spread, such as India, South America and Central America.

South Carolina has a Sickle Cell Disease State Plan developed by a group of dedicated partners who work to help mitigate this life-threatening disorder, said Dr. Traxler. We can all help increase awareness about sickle cell disease by sharing education and information within our communities, especially in minority or underserved communities that may struggle with access to routine health care.

In 2017, South Carolina established the South Carolina Sickle Cell Disease Advocacy Team, which remains focused on one common goal to improve the treatment and care received by individuals and their families who have sickle cell disease.

DHEC provides a printable sickle cell disease flyer available for anyone here. Organizations can order printed copies of the flyer for distribution by placing an order here. Learn more about the disease at cdc.gov/sicklecell.

###

About the South Carolina Sickle Disease Advocacy TeamMembers of the South Carolina Sickle Cell Disease Advocacy Team (SCSCDAT), who came together to develop the South Carolina Sickle Cell Disease State Plan, include physicians, hematologists, government agencies non-profit organizations, healthcare management organizations and individuals living with SCD and their family members.

Media Contacts:

COBRA Sickle Cell Program http://www.cobraagency70.com/home.html sicklecell@cobraagency70.com 843-225-4870

Louvenia D. Barksdale Sickle Cell Anemia Foundation http://www.ldbarksdalesc.org/ ldbarksdalesc@gmail.com 864-582-9420

James R Clark Memorial Sickle Cell Foundation http://www.jamesrclarksicklecell.org office@jamesrclarksicklecell.org 803-799-6471

Orangeburg Area Sickle Cell Anemia Foundation orangeburgsickle@gmail.com 803-534-1716

The B Strong Group thebstronggroup.org thebstronggroup@gmail.com 803-875-1266

DRE 365 (Dream Reach Empower) dre365sc@gmail.com 803-759-0700

Link:
DHEC Supports Awareness and Education during National Sickle Cell Awareness Month - SCDHEC

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the fourth quarter and full-year ended June 30, 2021 (FY2021).

During this calendar year we made significant progress in both regulatory and clinical outcomes for our lead product candidate, remestemcel-L, after experiencing a disappointing set-back last year said Silviu Itescu, Chief Executive of Mesoblast. We are pleased with recent recommendations by FDAs CBER to meet with the review team and address remaining CMC items for remestemcel-L in the treatment of steroid-refractory acute graft versus host disease in children. Additionally, our most recent meeting with the FDA has provided clarity on the pathway towards an emergency use authorization for remestemcel-L in the treatment of COVID ARDS.

Operational Highlights

Remestemcel-L Outcome of recent meeting with FDA on regulatory pathway for emergency use authorization in the treatment of COVID-19 ARDS:

Remestemcel-L in the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in children:

Rexlemestrocel-L in the treatment of chronic heart failure and chronic low back pain:

Manufacturing

Financial Highlights

DETAILED CLINICAL ACTIVITIES FOR THE FISCAL YEAR FY2021

Remestemcel-L

Acute Respiratory Distress Syndrome due to COVID-19

Mesoblast recently presented results from the randomized controlled trial of remestemcel-L in 222 ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) at the biennial Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases conference hosted by the University of Vermont, Burlington, VT, and at the International Society for Cell & Gene Therapy (ISCT) Scientific Signatures Series event on Cell and Gene-Based Therapies in Lung Diseases and Critical Illnesses.

The presented data included improved respiratory function in patients treated with remestemcel-L, as well as 90-day survival outcomes showing remestemcel-L significantly reduced mortality by 48% at 90 days compared to controls in a pre-specified exploratory analysis of 123 treated patients under 65 years old. The trial had been halted after the third interim analysis since the 30-day primary endpoint would not be attained.

Key presentation findings were:

Mesoblast plans to move forward with an additional Phase 3 trial in COVID-19 ARDS with the next step being to agree with the FDA the final protocol and potency assay.

Inflammatory Bowel Disease Crohns Disease and Ulcerative Colitis

A randomized, controlled study of remestemcel-L delivered by an endoscope directly to areas of inflammation and tissue injury in up to 48 patients with medically refractory Crohns disease and ulcerative colitis commenced at Cleveland Clinic in October 2020. The investigator-initiated study is the first in humans using local cell delivery in the gut and will enable Mesoblast to compare clinical outcomes using this delivery method with results from an ongoing randomized, placebo-controlled trial in patients with biologic-refractory Crohns disease where remestemcel-L was administered intravenously.

Rexlemestrocel-L

Chronic Heart Failure

The results from the landmark DREAM-HF randomized controlled trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L (REVASCOR) or control sham, demonstrated that a single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes, and cardiac deaths. The trials primary endpoint of reduction in volume overload related hospitalizations was not achieved. The results of this trial identify New York Heart Association (NYHA) class II HFrEF patients as the optimal target population for greatest rexlemestrocel-L treatment effect, and therefore a focus for developing rexlemestrocel-L in the largest market in heart failure.

The incidence of heart attacks and strokes were reduced by 60% over a median follow-up period of 30 months following a single dose of rexlemestrocel-L in the entire population of 537 treated patients. The incidence of death from cardiovascular causes was reduced by 60% in the 206 patients with NYHA class II disease, a significant reduction which was evident in both ischemic and non-ischemic subgroups as well as diabetic and nondiabetic patients.

The results also show that the NYHA class II patients in the control group, following an initial period of approximately 20 months of disease stability, progressed to cardiac death rates in-line with NYHA class III patients. NYHA class II patients treated with a single dose of rexlemestrocel-L did not show such cardiac death progression.

The combination of the three pre-specified outcomes of cardiac death, heart attack or stroke into a single composite outcome - called the three-point major adverse cardiovascular events (MACE) is a well-established endpoint used by the FDA to determine cardiovascular risk. Rexlemestrocel-L reduced this three-point MACE by 30% compared to controls across the entire population of 537 treated patients. In the NYHA class II subgroup of 206 patients, rexlemestrocel-L reduced the three-point MACE by 55% compared to controls.

Mesoblast expects feedback from the FDA in the next quarter on the potential pathway to US regulatory approval for rexlemestrocel-L in patients with chronic heart failure.

Chronic Low Back Pain due to Degenerative Disc Disease

The results from the randomized controlled trial of its allogeneic mesenchymal precursor cell (MPC) therapy rexlemestrocel-L in 404 enrolled patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to conventional treatments indicate that a single injection of rexlemestrocel-L+hyaluronic acid (HA) carrier may provide a safe, durable, and effective opioid-sparing therapy for patients with chronic inflammatory back pain due to degenerative disc disease, and that greatest benefits are seen when administered earlier in the disease process before irreversible fibrosis of the intervertebral disc has occurred. The trial's composite outcomes of pain reduction together with functional responses to treatment were not met by either MPC group.

The rexlemestrocel-L+HA treatment group achieved substantial and durable reductions in CLBP compared to control through 24 months across the entire evaluable study population (n=391) compared with saline controls. Greatest pain reduction was observed in the pre-specified population with CLBP of shorter duration than the study median of 68 months (n=194) and subjects using opioids at baseline (n=168) with the rexlemestrocel-L+HA group having substantially greater reduction at all time points (1, 3, 6, 12, 18 and 24 months) compared with saline controls. There was no appreciable difference in the safety of MPC groups compared to saline control over the 24-month period of follow-up in the entire study population. In subjects using opioids at baseline, the MPC+HA demonstrated a reduction in the average opioid dose over 24 months, while saline control subjects had essentially no change.

There is a significant need for a safe, efficacious, and durable opioid-sparing treatment in patients with chronic low back pain due to severely inflamed degenerative disc disease. Mesoblast has filed a request and expects to receive feedback from the FDA on the pathway to US regulatory approval in patients with chronic low back pain due to degenerative disc disease.

Intellectual Property

Mesoblast has an extensive patent portfolio with over 1,000 patents and patent applications across 77 patent families, and patent terms extending through 2041. These patents cover composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells, and provide strong commercial protection for our products in all major markets, including the United States, Europe, Japan and China. During the fiscal year Mesoblast has significantly expanded its patent portfolio, focusing on areas of its strategic commercial interests.

Licensing agreements with JCR, Grnenthal, Tasly and Takeda highlight the strength of Mesoblast's extensive intellectual property portfolio covering mesenchymal lineage cells. Mesoblast will continue to use its patents to prosecute its commercial rights as they relate to its core strategic product portfolio. When consistent with the Companys strategic objectives, it may consider providing third parties with commercial access to its patent portfolio.

DETAILED FINANCIAL RESULTS

Financial Results for the Year Ended June 30, 2021 (FY2021)

In August we entered into a contractual amendment to extend the interest-only period of its current senior debt facility to at least January 2022 and as a result no loan repayments will be required prior to January 2022. Mesoblast is in active discussions to refinance the facility.

We expect to recognize the existing US$21.9 million of remestemcel-L pre-launch inventory on the balance sheet if we receive FDA approval.

As a result of the above and other remeasurements on revaluation of assets and liabilities, the loss after tax for FY2021 was US$98.8 million compared to US$77.9 million for FY2020. The net loss attributable to ordinary shareholders was 16.33 US cents per share for FY2021, compared with 14.74 US cents per share for FY2020.

Conference Call

There will be a webcast today, beginning at 7.00pm EDT (Monday, August 30, 2021); 9.00am AEST (Tuesday, August 31). It can be accessed via:https://webcast.boardroom.media/mesoblast-limited/20210826/NaN61036c41df5665001c97fc67

The archived webcast will be available on the Investor page of the Companys website: http://www.mesoblast.com

About Mesoblast

Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Companys proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has completed Phase 3 trials of rexlemestrocel-L for advanced chronic heart failure and chronic low back pain. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

References / Footnotes

Forward-Looking Statements

This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of Mesoblasts preclinical and clinical studies, and Mesoblasts research and development programs; Mesoblasts ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblasts ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblasts product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblasts product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblasts ability to enter into and maintain established strategic collaborations; Mesoblasts ability to establish and maintain intellectual property on its product candidates and Mesoblasts ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblasts expenses, future revenues, capital requirements and its needs for additional financing; Mesoblasts financial performance; developments relating to Mesoblasts competitors and industry; and the pricing and reimbursement of Mesoblasts product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

Originally posted here:
Operational Highlights and Financial Results for the Year Ended June 30, 2021 - GlobeNewswire

VANCOUVER, British Columbia, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Victory Square Technologies Inc. (Victory Square or Company) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides investors access to a diverse portfolio of next generation technology companies in key sectors including: the Creator Economy, Digital Health, Gaming, Web 3.0, VR/AR and Green Tech, announces it has filed its consolidated condensed interim financial statements and associated managements discussion and analysis (MD&A) for the three and six months ended June 30, 2021.

"Q2 2021 was another strong quarter for Victory Square in which we achieved a sixth consecutive quarter with positive net income & earnings per share, issued a share dividend, and listed GameOn (CSE:GET). In addition to closing our investment in Stardust Solar Technologies Inc. (Stardust), we closed an oversubscribed financing for Immersive, launched DiscreetCare.com and Covalent Network Corporation completed a $10,000,000 USD public sale of their CQT token, said Shafin Diamond Tejani, Chief Executive Officer of Victory Square.

Financial Highlights for the three months ending June 30, 2021:

Financial Highlights for the six months ending June 30, 2021:

*During the three months ended June 30, 2021, the company had net income from continuing operations of $1,144,572, adjusted for non-cash costs for share based payments of $519,548, and non-controlling interest for the period of $558,060, the adjusted net income of the Company was $2,222,180. Adjusted basic earnings per share was $0.02 and diluted earnings per share was $0.02.

* During the six months ended June 30, 2021, the Company had net income from continuing operations of $4,583,453, adjusted for non-cash costs for share-based payments of $2,085,606 and non-controlling interest for the period of $984,196, the adjusted net income of the Company was $7,653,255. Adjusted basic earnings per share was $0.08 and diluted earnings per share was $0.07.

The Companys consolidated financial statements for the quarter ending June 30, 2020 along with its MD&A are available under the Companys profile on SEDAR at http://www.sedar.com.

Business Highlights for the three months ending June 30, 2021:

April 2021

May 2021

June 2021

Subsequent business highlights to June 30, 2021:

July 2021

August 2021

Outlook:

The Company expects to focus on the following primary goals for the next 90 - 120 days are:

Finally, Victory Square integrates a strong ESG (environmental, social and corporate governance) component throughout its operations. Our portfolio highlights minority entrepreneurs, often overlooked by traditional investors, including many from developing countries. We are also dedicated to giving back to the communities in which we serve and operate. The Companys mandate is to assist organizations through its time, talent and treasure. The Company is committed to organizations that provide services in the youth, mental health, special needs, sport, tech, education, marginalized groups, First Nations, and accessibility sectors.

The company and the management team contributed approximately $500,000 in donations to: Variety The Children Charity of BC, CKNW KIDS FUND, Simon Fraser University Tech Camp, The BC Sports Hall of Fame & Museum, Covenant House Vancouver, YWCA, Coast Mental Health, The Cerebral Palsy Association of BC, Mealshare and the BC Childrens Hospital Foundation. These gifts are in conjunction with VSTs GIVING BACK pledge made by its Executive, Staff, and Board.

We are living in the midst of the 4th Industrial Revolution; The Tech Revolution that will undoubtedly change everything as we know it, said Shafin Diamond Tejani. Digital health, AR/VR, Cybersecurity, Gaming, Sports, Entertainment, and Web 3.0 are sectors that Victory Square has invested in. We offer investors the chance to invest in the most exciting tech trends all in one place.

Check out VictorySquare.com and sign up to VSTs official newsletter at http://www.VictorySquare.com/newsletter.

On behalf of the Board of Directors

Shafin Diamond TejaniDirector and Chief Executive OfficerVictory Square Technologies Inc.www.victorysquare.com

For further information about Victory Square, please contact:

Investor RelationsContact Edge Communications GroupEmail: ir@victorysquare.comTelephone: 604 283-9166

Media RelationsContact Howard Blank, DirectorEmail: howard@victorysquare.com

ABOUT VICTORY SQUARE TECHNOLOGIES INC.

Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed for fast-track growth. VSTs sweet spot is cutting-edge tech thats shaping the 4th Industrial Revolution. Our corporate portfolio consists of 20+ global companies using AI, VR/AR, and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups

VST isnt your ordinary investor. With real skin in the game, were committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best build, innovate and disrupt. In 24-36 months, youll scale and be ready to monetize.

What we do differently for investors

For investors, we offer early-stage access to the next unicorns before theyre unicorns. Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies. Because we focus on market-ready solutions that scale quickly, were able to provide strong and stable returns while also tapping into emerging global trends with big upsides.

VST is a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).

For more information, please visit http://www.victorysquare.com.

ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)

The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets."

This news release is qualified in its entirety by its interim financial statements and associated MD&A for the period ended June 30, 2021, copies of which are available on the Companys profile on SEDAR at http://www.sedar.com. In the case of any conflict between this news release and the financial statements and MD&A, the information provided in the financial statements and MD&A shall prevail. Investors are referred to the entirety of the financial statements and MD&A.

FORWARD-LOOKING INFORMATION

This news release contains forward-looking information within the meaning of applicable securities laws relating to the outlook of the business of Victory Square and its portfolio companies, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries and portfolio companies and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as believes, expects, anticipates, estimates, intends, plans, continues, project, potential, possible, contemplate, seek, goal, outlook or similar expressions, or may employ such future or conditional verbs as may, might, will, could, should or would, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Although Victory Square believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statements has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Victory Squares control, including, but not limited to, the risk factors discussed in the continuous disclosure materials of the Victory Square which are available under the Victory Squares profile on SEDAR at http://www.sedar.com. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

See the original post here:
Victory Square Technologies Reports Record 6th Consecutive - GlobeNewswire

Actor Rubina Diaik says she keeps a balance on social media as otherwise it is easy to get overwhelmed.

PUBLISHED ON AUG 28, 2021 03:40 PM IST

Rubina Dilaiks popularity has been rising each year. With her numerous fans supporting her personal and professional moves, the Shakti actor admits that her heart is filled with gratitude for all their love. She adds, As an artist, the biggest reward for you is the love and appreciation that you get. That doesnt match the awards out there. I have realised that life of an artist is dedicated to the audiences. We strive, entertain and perform for our audiences. When we are loved and accepted immensely, that gives us the validation of who we are.

Recently, Dilaik was number seven on Twitters list of top 10 hashtags in the first half of 2021. She shares that after her Bigg Boss win earlier this year, she realised the impact of social media. She explains further, If I said I am happy being talked about globally, then it would be an understatement. But, for me, the takeaway from Twitter trends is all about the love of my fans. I strive that my work should speak for me and recognition for that work is what we all look for. To be acknowledged on a global platform for your work is unmatchable. These trends prove how much people love me, talk about my work and the effort they put into showing it. It is commendable that they are so sincerely dedicated and reiterating their love for me that I am bound to be even more hard work so as to not let them down.

While the actor enjoys social media, she also states that it is just a tool between her and her fans and one doesnt need to go nuts about it. I keep everything in life in a balanced state it also applies to my appearance on social media and its impact on my state of mind. Fitting into every trend, keeping a tab on what people say about you or replying to hateful comments is not important. Be who you are and know how to use social media. I am mindful of what I put out, what I want to represent on the platform and also what I want to absorb from it. I dont pay attention to the comments and trolling.

She adds, When I notice how much effort and energy is put in by my fans to make my music videos or my videos viral, I acknowledge that. We need to learn the art of rejection and acknowledgement. At the end, it is for your own sanity. I am not swayed by what is happening on social media and nor can I keep posting because I want attention. There is a thin line which helps me balance. I have to keep a balance or things can get overwhelming, she signs off.

Get our daily newsletter

Thank you for subscribing to our dailynewsletter.

See the article here:
Rubina Dilaik: Social media is a platform for you to explore; its not there to control you - Hindustan Times